Fannie Mae, Freddie Mac shares tumble after conservatorship comments
On Friday, JMP Securities analyst Roy Buchanan adjusted the price target for Dynavax Technologies (NASDAQ:DVAX), increasing it to $33.00 from the previous target of $29.00. The stock, currently trading at $13.33, sits near its 52-week high of $13.89. Despite the change, the analyst has chosen to keep a Market Perform rating on the stock. According to InvestingPro data, analyst targets for DVAX range from $12 to $31, reflecting mixed sentiment on Wall Street.
Dynavax Technologies has reported its fiscal year 2024 results, aligning with the figures previously announced in January. The company has successfully executed half of its planned $200 million share repurchase program, with $100 million worth of shares bought back. Plans are in place to acquire the remaining $100 million by the end of the year. InvestingPro analysis shows the company maintains strong financial health with a GOOD overall score, holding more cash than debt on its balance sheet.
The company’s guidance for its hepatitis B vaccine, HEPLISAV-B, for the year 2025 forecasts revenues between $305 million and $325 million. According to Buchanan, this guidance is slightly below both his expectations and the consensus. However, he noted that the first quarter of 2025 has begun strongly. With a current P/E ratio of 84.49 and revenue of $260.81 million in the last twelve months, investors can access detailed valuation metrics and 8 additional key insights through InvestingPro’s comprehensive research platform.
Dynavax’s management has expressed a positive outlook on the company’s strategy to enhance shareholder value. They believe that acquiring value-adding, late-stage assets in the infectious disease sector is the most effective approach to maximize the potential of HEPLISAV-B, which they consider a best-in-class hepatitis B vaccine.
The ongoing share buyback program and the company’s strategic focus on expanding its portfolio in the infectious disease space underscore Dynavax’s commitment to growth and value creation for its shareholders.
In other recent news, Dynavax Technologies Corporation reported its Q4 2024 earnings, showcasing an earnings per share (EPS) of $0.05, which exceeded the forecasted $0.04. However, the company reported revenue of $71.1 million, missing the expected $72.44 million. Despite this revenue miss, the company saw record HEPLISAV B sales with a 39% year-over-year increase, contributing to a full-year net sales total of $268 million, up 26% from the previous year. Dynavax also reported a strong cash position at year-end with $714 million and an adjusted EBITDA of $52 million, marking an over 300% year-over-year increase. The company projects HEPLISAV B net product revenue to be between $315 million and $325 million for 2025, indicating an expected 17% year-over-year growth. Analysts from firms such as William Blair and Citizens have shown interest in Dynavax’s strategic initiatives, including its shingles vaccine development. Dynavax remains focused on expanding its market share and advancing its product pipeline, with ongoing efforts in vaccine programs for shingles and plague.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.